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Abstract The subtilase subtilisin kexin isozyme-1 (SKI-1)/site 1
protease (S1P), has been implicated in the processing of Lassa
virus glycoprotein C (GP-C) precursor into GP1 and GP2 that
are responsible for viral fusion with the host cell membrane.
Here, we studied in vitro the kinetics of this cleavage by hSKI-1
using an intramolecularly quenched fluorogenic (IQF) peptide,
Q-GPC251ÿ263 [Abz-251Asp-Ile-Tyr-Ile-Ser-Arg-Arg-Leu-
LeusGly-Thr-Phe-Thr263-3-NitroTyr-Ala-CONH2], containing
the identified site. The measured Vmax app/Km app was com-
pared to those for other IQF SKI-substrates. Q-GPC251ÿ263 is
cleaved 10-fold more efficiently than the previously known best
SKI-substrate, Q-hproSKI134ÿ142. This study confirmed the role
of SKI-1 in GP-C processing and provides a novel, rapid and
efficient enzymatic assay of SKI-1. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Viral infections are often mediated by the cleavage of asso-
ciated precursor surface glycoproteins into their functionally
active forms [1^3]. Following proteolysis, the smaller ‘acti-
vated’ polypeptide fragments become highly virulent and fu-
sogenic to the host cell membrane leading to the onset or
progression of infection [4,5]. It is now recognized that besides
viral protease(s), single or multiple host enzymes also play a
crucial role in viral pathogenesis by providing necessary assis-
tance to the activation of surface glycoprotein of the invading
virus particle. Hence, identifying the host protease/s respon-
sible for maturation of precursor glycoproteins and silencing
their activity via speci¢c inhibitors may provide an e¡ective
alternative to viral therapeutics [5^7]. Several studies indicated
that the cellular proteases ‘proprotein convertases’ (PCs) (re-
viewed in [8]) are responsible for proteolytic maturation of
envelope glycoproteins of HIV [4,5], Ebola [9], and other
viruses [2,7,10]. It was further demonstrated that PC-speci¢c
inhibitors are capable of blocking these cleavages and display
antiviral properties [5,7,11]. The primary description of such
inhibitors (against furin) capable of blocking the cleavage of
HIV-1 glycoprotein gp160 was reported by Hallenberger et al.
[5]. PCs are Ca2-dependent serine proteases related to the
family of subtilases that include bacterial subtilisin and yeast
kexin. These cleave proproteins at selected single or pairs of
basic residues characterized by the motif R/H/KXK/RRs or
R/H/KXXRs [8], where X = any amino acid except Cys. Re-
cently a paralog of PCs, called ‘subtilisin kexin isozyme-1’
(SKI-1) or site 1 protease (S1P) has been discovered. The
latter cleaves at the carboxy-terminus of non-basic amino
acids within the consensus sequence R/KX-hydrophobic-L/I/
S/Ts [12^15]. So far ¢ve physiological substrates of SKI-1
have been identi¢ed. They are proBDNF [13,14], SREBPs
[12,15], the transcription factor ATF-6 [16], pro-somatostatin
[17] and the prodomain of SKI-1 itself [14,18]. Recently SKI-1
has been identi¢ed by Lenz et al. as the cleavage enzyme of 76
kDa Lassa virus precursor glycoprotein C (GP-C) into two
active subunits, the N-terminal GP-1 and the C-terminal
membrane-bound GP-2 [19]. Earlier, the site of this cleavage
had been indicated by the same group as RRLL259sGTF [20].
Lassa virus, a member of the arenavirus family, mostly found
in West Africa, causes hemorrhagic fever with £u-like
symptoms, replication in the cytoplasm, and bud-ding at the
plasma membrane [21,22]. Between 100 000 and 500 000 cases
have been reported annually, with a mortality rate of V15%,
particularly among the pregnant women, while their fetuses
have the highest rate of mortality (92^100%). Infection is gen-
erally caused by exposure to the virus via infected feces, sal-
iva, etc., through broken skin and mucous membranes
[19,21,22]. To further con¢rm the role of SKI-1 in the proteo-
lytic activation of GP-C and to develop a rapid bioassay for
its activity, we prepared an internally quenched £uorogenic
(IQF) peptide [7,23,24] encompassing the GP-C cleavage
site. The measured kinetic parameter Vmax app/Km app was
compared with those for other IQF peptides derived from
proregion of hSKI-1, hproBDNF and potential SKI-1 sub-
strates. The latter include the proposed 19 kDa cleavage site
of malaria parasite Plasmodium falciparum merozite surface
protein 1 (PfMSP-1) [25]. The Cys-rich 19 kDa fragment is
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retained by the merozite during erythrocyte invasion and the
processing leading to its formation plays an essential role in
malarial infection [26].
2. Materials and methods
All £uorenylmethyloxycarbonyl (Fmoc)-amino acids (L-con¢gura-
tion), the coupling agents and solvents were purchased from PE Bio-
systems Inc. (Framingham, MA, USA), Calbiochem Novabiochem,
(San Diego, CA, USA), Chem-Impex International Inc., (Wood
Dale, IL, USA) and Aldrich Chemical Company (Milwakee, WI,
USA). Amino acid analyses were performed following 24 h hydrolysis
in 6 N HCl at 110‡C in vacuo using a Dionnex autoanalyzer [7].
Reverse-phase high performance liquid chromatography (RP-
HPLC) was performed on a Rainin (Dynamax) instrument, using a
10 W, 300 Aî C18 column [Jupiter, Phenomenex, 0.46U25 cm (analyt-
ical) or 1U25 cm (semipreparative)]. The bu¡ers comprised an aque-
ous 0.1% (v/v) tri£uoroacetic acid (TFA) solution and an organic
phase of CH3CN containing 0.1% (v/v) TFA. Peptides were eluted
with a 1%/min linear gradient (5^60%) of 0.1% aqueous TFA/CH3CN
at a £ow rate of 1 ml/min (analytical run) or 2 ml/min (semiprepar-
ative run), following a 5 min isocratic at 5% of 0.1% TFA/CH3CN.
The elution of the peptides was monitored by UV absorbancy (V= 210
or 230 nm) and by £uorescence measurement (Dynamax £uorescence
detector, model FL-2) at Vex and Vem ¢xed at 320 and 420 nm respec-
tively. All £uorometric assays were performed with a specto£uorom-
eter instrument (Gemini, Molecular Dynamics, Sunnydale, CA, USA)
as described [7].
2.1. Source of soluble recombinant hSKI-1
The soluble hSKI-1 was obtained as described using a BTMD
hSKI-1 construct ending at PGRYNQE997 [14]. Following a 6 h in-
cubation of vaccinia virus infected BTMD SKI-1 recombinant in HK-
293 cells, the conditioned medium was concentrated (V15-fold) using
centricon-30 (Amicon, USA), dialyzed and stored with 40% glycerol
at 320‡C before use.
2.2. Design of IQF peptide substrates
Several IQF-peptides with an electron donor 2-amino benzoic acid
(2-Abz) and an acceptor 3-nitro tyrosine (Tyx) group attached respec-
tively to the amino and carboxy-terminals of the peptide were de-
signed. An additional Ala residue was incorporated at the carboxy-
terminus to facilitate synthesis. Table 1 lists all nine IQF peptides.
Among these, Q-hSKI134ÿ142 and Q-hSKI132ÿ142 were previously re-
ported by us [14]. Another peptide, FL-GPC251ÿ259, representing the
NH2-terminal portion preceeding the GP-C cleavage site was also
synthesized for generating a standard curve needed for quenching
corrections (see below). All peptides, except FL-GPC251ÿ259, were pre-
pared with the carboxy-terminal in the amide (CONH2) form.
2.3. Peptide synthesis
All peptides were synthesized on a solid phase automated peptide
synthesizer (Pioneer model, PE-PerSeptive Biosystems, Framingham,
MA, USA), using O-hexa£uorophospho-[7-azabenzotriazol-1-yl]-
N,N,NP,NP-tetramethyluronium/diisopropyl ethyl amine-mediated
Fmoc chemistry [7,14] and polyamino linker polyethylene glycol resin.
For incorporation of unnatural amino acids, 2-Abz and Tyx, a double
coupling each with extended cycle was used.
2.4. Peptide puri¢cation and mass spectrometry (MS)
Peptides were puri¢ed by RP-HPLC using C18 semipreparative and
analytical columns. They were characterized by matrix-assisted laser
desorption ionization time of £ight MS (MALDI-tof; Voyageur DE-
Pro, PerSeptive Biosystems) using CHCA matrix [7,14].
2.5. Enzyme assay
For measurement of SKI-1 activity, the enzyme sample was incu-
bated at 37‡C with varying concentrations of IQF peptides (Table 1).
For each assay, 10 Wl of the enzyme sample was added to a solution
containing the peptide (100 WM) in bu¡er consisting of 25 mM Tris^
HCl+25 mM 4-morpholine ethane sulphonic acid monohydrate, pH
7.4, 2.5 mM CaCl2, in a total volume of 100 Wl. Both on-line and stop
time assays were performed with Vex and Vem at 320 and 420 nm
respectively.
2.6. Correction for £uorescence quenching
Consistent with earlier studies [7,23], we noted a signi¢cant inter-
molecular quenching of the released £uorescent material by the un-
digested substrate, especially at high concentrations of the substrate.
This is corrected by using a standard quenching curve derived from
each IQF peptide and FL-GPC251ÿ259 [23].
2.7. Determination of kinetic parameters Vmax app and Km app and
sites of cleavages
For measurements of Vmax app and Km app, hSKI-1 (10 Wl) was
incubated (4^8 h) with increasing concentrations (1^20 WM or more)
of each IQF peptide in 100 Wl of bu¡er in a 96-well microtiter plate at
37‡C. The rate of hydrolysis was obtained from the changes in £uo-
rescence readings and the values transformed into Wmol/h of peptide
cleaved by using standard curve and quenching corrections [7,14,23].
Data were collected in duplicates and each value is the mean of three
independent experiments. Vmax app and Km app were calculated as
described [7,14,23]. For determination of site of cleavage, each digest
was analyzed by RP-HPLC using the C18 analytical column followed
by MALDI-tof MS of each isolated peak.
3. Result and discussion
3.1. Design of IQF peptide substrates for SKI-1
IQF peptides (Table 1) were designed from the amino acid
sequences around the processing sites of substrates and poten-
tial substrates of SKI-1. These include the GP-C cleavage site
RRLL259sGT, the hproSKI-1 primary (RSLK137sYA) and
secondary (RRLL186sRA) activation sites, the proposed ma-
larial PfMSP-1 processing site (KFQDML1605sNIS) of the 19
kDa form and the hproBDNF cleavage site (RGLT57sSL)
resulting in the 28 kDa form. We have also included two
additional IQF peptides derived from the PC-processing site
of Hong Kong virus glycoprotein [27] and NRD convertase
processing site of prodynorphin [28], since they also contain a
potential site of cleavage for SKI-1 (RKKRGL332sTyx-A
and RRIQ9sTyx respectively).
3.2. Digestion of Q-GPC251ÿ263 by recombinant SKI-1
Among the nine peptides tested, only Q-GPC251ÿ263, Q-
SKI-1134ÿ142, Q-SKI-1132ÿ142, Q-SKI-1181ÿ187+LE, Q-SKI-
1178ÿ188 and Q-HKV318ÿ332 were cleaved in vitro by SKI-1
with varying kinetic e⁄ciencies. In all cases, the cleavage
occurs mostly at the physiological site (Table 1). The exact
cleavage site was con¢rmed by RP-HPLC of the digest
and MALDI-tof MS analysis of the materials under the col-
lected peaks (Table 2). Fig. 1A, shows that Q-GPC251ÿ263
is almost fully cleaved by SKI-1 in 12 h. This is con¢rmed
by near disappearance of the parent peptide peak [retention
time (Rt)V45.3 min, mass/charge (m/z) observed = 1949.8
(M+H), calculated = 1951] and the emergence of two addi-
tional peaks at 27.1 and 39.1 min, identi¢ed respectively as the
cleaved fragments C-terminal GTFT-Tyx-A-NH2 [m/z ob-
served = 702.06 (M+H), calculated = 701.2] and N-termi-
nal Abz-DIYISRRLL-OH [m/z observed = 1271.9 (M+H),
calculated = 1270.2]. The result con¢rmed the previously ob-
served in vivo cleavage by SKI-1 of GP-C at RRLL259sGTF
[19,20]. Fig. 1 also reveals that even upon prolonged incuba-
tion, no cleavage at the potential R-R-L-L-G260sT-F site is
observed. This suggests that despite the presence of P4 Arg
and P2 Leu, SKI-1 does not accept a Gly at P1 position, an
alkyl hydrophobic residue at P3 position or an aromatic hy-
drophobic residue at P2P position or a combination thereof.
As expected, treatment of Q-GPC251ÿ263 with control wild-
type (WT) medium concentrate produced no peptide hydro-
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lysis (Fig. 1C). Moreover RP-HPLC of 4 h digest of Q-
GPC251ÿ263 with varying amounts of SKI-1 (2.5, 5, 7.5 and
10 Wl) showed a gradual diminution of peak intensity for the
parent peptide (RtV45.4 min) (data not shown). A similar
digestion pro¢le was also noted with time of incubation for
a ¢xed amount of the enzyme.
3.3. Digestion of other IQF peptides by recombinant SKI-1
Both Q-hSKI134ÿ142 and Q-hSKI132ÿ142 were cleaved by
SKI-1 at the RSLK137sY site (major), as observed earlier
[14,15], and at the RSLKYA139s site (minor). This is con-
¢rmed by RP-HPLC analysis of each peptide digest showing
the presence of peaks for the parent peptide and cleaved prod-
Table 1
List of various IQF peptides
Important basic (Arg/Lys) and hydrophobic (Leu/Ile) residues are indicated by underline. The arrow indicates the potential cleavage site for
SKI-1.
Table 2
MALDI-tof MS data of various fractions obtained from RP-HPLC chromatograms of SKI-1 digests of Q-GPC251ÿ264 and Q-hSKI134ÿ142
FEBS 25867 28-3-02
A. Basak et al./FEBS Letters 514 (2002) 333^339 335
Fig. 1. RP-HPLC chromatograms showing the separation of diges-
tion products of Q-GPC251ÿ263 (10 Wg) by hSKI-1 (10 Wl) after (A)
4 h, (B) 12 h incubation and (C) by HK293 control medium con-
centrate (10 Wl) following 12 h incubation. D: Peptide alone. The
separation was monitored on-line by both UV absorbance (210 nm)
and £uorescence (Vex = 320 nm and Vem = 420 nm) (data not shown).
The peaks were identi¢ed by amino acid composition and MALDI-
tof MS (Table 2). Peak 39.1 min = £uorescent N-terminal fragment
(Abz-DIYISRRLL-OH), peak 27.1 min = non-£uorescent C-terminal
fragment (GTFT-Tyx-A-NH2), and peak 45.2 min = undigested Q-
GPC251ÿ263.
Fig. 2. RP-HPLC chromatograms on digestion products of Q-
hSKI134ÿ142 by hSKI-1 (10 Wl) following 14h incubation. The chro-
matograms were monitored on line by both UV (top, V= 214 nm)
and £uorescence (bottom, Vex = 320 nm, Vem = 420 nm) detectors.
The peaks were identi¢ed by amino acid composition and MALDI-
tof MS (Table 2). Peak 23.4 min = £uorescent N-terminal fragment
(Abz-RSLK-OH), peak 24.4 min = corresponding non-£uorescent C-
terminal fragment (YAESD-Tyx-A-NH2), peak 26.2 min (minor) =
£uorescent N-terminal fragment (Abz-RSLKYA-OH) generated by
cleavage at alternate site (thin arrow), peak 19.8 min = correspond-
ing non-£uorescent C-terminal fragment (ESD-Tyx-A-NH2) and
peak 32.8 min = undigested Q-SKI134ÿ142.
Fig. 3. Michaelis^Menten curves for the cleavages of various IQF peptides by hSKI-1 following 4^8 h incubation. A: Q-GPC251ÿ263, B: Q-
hSKI134ÿ142 (open triangle), Q-hSKI132ÿ142 (solid circle), and C: hSKI181ÿ187+LE (top), Q-hSKI178ÿ188 (middle) and Q-HKV318ÿ332 (bottom).
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ucts. Fig. 2 shows the RP-HPLC chromatogram of a 12 h
digest of Q-hSKI134ÿ142. The peptides eluting at Rt 32.8,
24.4 and 23.4 min were respectively characterized as undi-
gested peptide (m/z observed = 1465.7 (M+H), calcu-
lated = 1463.3], the C-terminal YAESD-Tyx-A-NH2 [m/z ob-
served = 861.6 (M+H), calculated = 860.1] and the highly
£uorescent N-terminal Abz-RSLK-OH [m/z observed = 622.3
(M+H), calculated = 621.l], con¢rming a cleavage at
RSLK137sY. The peptide eluting at Rt = 26.2 min, visible
with the £uorescence detector, was identi¢ed as the N-termi-
nal Abz-RSLKYA-OH, [m/z observed = 855.6 (M+H), calcu-
lated = 854.1], indicating an additional relatively minor cleav-
age at RSLKYA139sE. The corresponding C-terminal
fragment of this cleavage [ESD-Tyx-A-NH2] was attributed
to the peak eluting at Rt = 19.8 min (m/z observed = 627.6,
calculated = 626.5). Q-hSKI181ÿ187+LE, Q-hSKI178ÿ188 and
Q-HKV318ÿ332 were all poorly cleaved by SKI-1 (Table 1),
as con¢rmed by MS and RP-HPLC analyses (not shown).
These data suggest that although P4 Arg is crucial for recog-
nition by SKI-1, a P6 Arg can compensate for the absence of
a P4 Arg.
3.4. Kinetic parameters, Vmax app and Km app
Graphic presentations used for the determination of
Vmax app and Km app using Michaelis^Menten plots of the
digestion of various IQF peptides by SKI-1 are shown in
Fig. 3A^C. The data (Table 3) indicate that Q-GPC251ÿ263 is
the most potent in vitro substrate of SKI-1. It is cleavedV10-
fold more e⁄ciently than the previously known best substrate
Q-SKI-1134ÿ142 [14]. Q-GPC251ÿ263 exhibited Vmax app and
Km app 45- and 4.6-fold higher than that for Q-SKI-
1134ÿ142. Vmax app/Km app ratio for SKI-1-mediated cleav-
age of Q-GPC251ÿ263 is respectively V100-, 175-, 258- and
515-folds higher than those of Q-SKI-1132ÿ142, Q-SKI-
1181ÿ187+LE, Q-SKI-l178ÿ188 and Q-HKV318ÿ332, respectively.
Thus, P4 Arg, alkyl hydrophobic groups at both P1 and P2
Fig. 4. Progress curves for the release of £uorescence upon incubation of Q-GPC251ÿ263, [Abz-DIYISRRLLsGTFTY(NO2)A-NH2], with (A)
various amounts of recombinant hSKI-1 (2.5, 5 and 7.5 Wl from bottom to top), and (B) WT control HK293 medium concentrate (expanded in
the enclosed inset). The £uorescence is monitored over 40 min at Vex = 320nm, Vem = 420 nm.
Table 3
Measured kinetic parameters of cleavages of various IQF peptides by soluble recombinant hSKI-1
Peptides Vmax (Wmol/h) Km app WM Vmax/Km app (h31 l31) Fold
Q-GPC251ÿ263 192.7 4.4 43.8 1.0
Q-hSKI134ÿ142 4.27 0.96 4.45a 0.102
Q-hSKI132ÿ142 1.86 4.28 0.44a 0.01
Q-hSKI-1181ÿ187+LE 5.87 23.08 0.25 0.0057
Q-hSKI178ÿ188 3.44 20.02 0.17 0.00388
Q-HKV318ÿ332 2.36 27.87 0.085 0.00194
Q-Dyn2ÿ9 No cleavage
Q-PfMSP-11600ÿ1608 No cleavage
Q-BDNF47ÿ58 No cleavage
aData were taken from our earlier study [14].
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and a small amino acid at P1P are favorable for SKI-1. More-
over, lack of processings of Q-Dyn2ÿ9 and Q-PfMSP-
11600ÿ1608 and a poor cleavage of Q-HKV318ÿ332 suggest that
the presence of highly hydrophobic and bulky unnatural ar-
omatic residue Tyx at P1P position is not accepted by SKI-1
nor a P6 Lys residue for P4 Arg. Moreover, unlike the PCs,
presence of consecutive basic residues at P4^P8 may not be
well accepted by SKI-1. Inability of SKI-1 to cleave Q-
BDNF47ÿ58 (Abz-47NGPKAGSRGLTsS58Tyx-A) in contrast
to hproBDNF50ÿ63 (50KAGSRGLTsSLADTF63), which is
readily processed by SKI-1 at the site indicated [14], suggests
that the unnatural aromatic Tyx residue at P2P position and/
or a Pro at P9 position (shown in bold) are not suitable for
recognition by SKI-1. Thus, a Tyx residue at P1P, P2P or P4P is
not accepted by SKI-1, even in the context of a sequence with
P4 Arg and P2 Leu.
3.5. Progress curve for the cleavage of Q-GPC251ÿ263 by SKI-1
Fig. 4A depicts progress curves for the cleavage of Q-
GPC251ÿ263 (100 WM) with variable amounts of hSKI-1 (2.5,
5 and 7.5 Wl). The £uorescence release following cleavage in-
creases gradually with enzyme used. Using Q-GPC251ÿ263 as
substrate, measured SKI activity in 7.5 Wl was 1.3- and 1.8-
fold higher than in 5 and 2.5 Wl respectively. Similarly, RP-
HPLC of respective digests con¢rm a systematic increase in
cleavage with enzyme levels. In contrast, WT medium did not
exhibit signi¢cant dose-dependent release of £uorescence (Fig.
4B). Furthermore, incubation of Q-GPC251ÿ263 with various
PCs, such as PC1, furin, PACE4, PC5, PC7 and kexin [8] did
not yield any signi¢cant release of £uorescence (data not
shown), suggesting its speci¢city towards SKI-1.
4. Conclusion
In summary, Q-GPC251ÿ263 is a highly potent and selective
£uorogenic substrate for SKI-1. It provides a very e⁄cient,
speci¢c and a rapid on-line assay for proteolytic activity of
SKI-1. The assay works best with 50^100 WM concentration
of the substrate. At higher concentration, the released £uores-
cence is signi¢cantly suppressed by the undigested peptide
while at lower concentration, the £uorescence release may
not be su⁄cient for precise measurement. The present study
provided in vitro evidence for the role of SKI-1 in the matu-
ration of Lassa virus GP-C and con¢rmed the previously
identi¢ed in vivo cleavage site RRLL259sGT [19,20]. This
highly sensitive bioassay of SKI-1 will ¢nd useful applications
to monitor SKI-1 activity in both tissue and animal models.
This is particularly signi¢cant in view of recent observation
that the selective disruption of SKI-1/S1P gene expression in
the liver of mice leads to a signi¢cant reduction in lipid and
cholesterol biosynthesis [29]. The assay will also help in the
development of speci¢c SKI-1 inhibitors that may function as
potential lipid-lowering agents for which a close to complete
enzyme inhibition is required in order to achieve signi¢cant
biological e¡ects.
Our study combined with previous ones revealed that (i)
SKI-1 recognizes best the consensus motif Arg-X-[Leu/Ile]-
[Lys/Ser/Thr/Leu]s, (ii) Arg but not Lys at P6 may compen-
sate partly for P4 Arg, (iii) the aromatic hydrophobic residue
Tyx at P1P, P2P or P4P positions is not accepted. The data also
suggests that possibly SKI-1 is not a candidate protease for
the maturation of merozite surface protein PfMSP-1 [26].
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